DEFERIPRONE ( DrugBank: Deferiprone )
6 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 4 |
| 6 | Parkinson disease | 15 |
| 18 | Spinocerebellar degeneration | 2 |
| 120 | Hereditary dystonia | 11 |
| 122 | Superficial siderosis | 2 |
| 233 | Wolfram syndrome | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03293069 (ClinicalTrials.gov) | January 1, 2019 | 21/9/2017 | Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis | Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone | Amyotrophic Lateral Sclerosis | Drug: Deferiprone;Drug: Placebo Oral Tablet | University Hospital, Lille | Ministry of Health, France | Active, not recruiting | 18 Years | 75 Years | All | 372 | Phase 2/Phase 3 | France |
| 2 | EUCTR2017-003763-35-FR (EUCTR) | 17/05/2018 | 05/03/2018 | conservative iron chelation by deferiprone for amyotrophic lateral sclerosis | Conservative Iron Chelation by Deferiprone as a disease-modifying Strategy for Amyotrophic Lateral Sclerosis using a Multicentre Parallel group, placebo controlled, Randomized clinical trial - FAIR ALS II | De novo Amyotrophic Lateral Sclerosis patients;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE | centre hospitalier universitaire de Lille | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 240 | Phase 3 | France | ||
| 3 | NCT02164253 (ClinicalTrials.gov) | September 2013 | 20/5/2014 | Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients | Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral Sclerosis | ALS (Amyotrophic Lateral Sclerosis);Iron Overload | Drug: Deferiprone | University Hospital, Lille | ApoPharma | Completed | 18 Years | 85 Years | All | 23 | Phase 2 | France |
| 4 | NCT02880033 (ClinicalTrials.gov) | February 2011 | 3/8/2016 | Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes | Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis | Parkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron Overload | Drug: deferiprone;Drug: placebo | University Hospital, Lille | NULL | Completed | 18 Years | 80 Years | All | 90 | N/A | France |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-004344-19-DE (EUCTR) | 07/02/2017 | 27/09/2016 | An international trial of deferiprone in patients with Parkinson’s disease | A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215 | Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone 600 mg delayed release tablet INN or Proposed INN: DEFERIPRONE | ApoPharma | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;Canada;Germany;United Kingdom | ||
| 2 | NCT02728843 (ClinicalTrials.gov) | October 12, 2016 | 31/3/2016 | Study of Parkinson's Early Stage With Deferiprone | A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease | Parkinson's Disease | Drug: Deferiprone;Drug: Placebo | ApoPharma | NULL | Completed | 18 Years | 80 Years | All | 140 | Phase 2 | Canada;France;Germany;United Kingdom |
| 3 | EUCTR2015-003679-31-NL (EUCTR) | 09/08/2016 | 24/05/2016 | New therapeutic strategy in Parkinson’s disease | Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II | De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE | Centre Hospitalier Régional et Universitaire de Lille | NULL | Not Recruiting | Female: yes Male: yes | 338 | Phase 2 | Portugal;Czech Republic;Spain;Austria;Netherlands | ||
| 4 | EUCTR2015-004344-19-FR (EUCTR) | 29/06/2016 | 20/04/2016 | An international trial of deferiprone in patients with parkinson’s disease | A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215 | Parkinson’s disease MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone 600 mg delayed release tablet INN or Proposed INN: DEFERIPRONE | ApoPharma Inc. | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;France;Canada;Germany;Italy;United Kingdom | ||
| 5 | EUCTR2015-003679-31-CZ (EUCTR) | 23/06/2016 | 28/01/2016 | New therapeutic strategy in Parkinson’s disease | Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II | De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE | Centre Hospitalier Régional et Universitaire de Lille | NULL | Not Recruiting | Female: yes Male: yes | 338 | Phase 2 | Portugal;Czech Republic;Spain;Austria;Netherlands | ||
| 6 | EUCTR2015-003679-31-PT (EUCTR) | 18/04/2016 | 28/01/2016 | New therapeutic strategy in Parkinson’s disease | Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II | De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE | Centre Hospitalier Régional et Universitaire de Lille | NULL | Not Recruiting | Female: yes Male: yes | 338 | Phase 2 | Portugal;Czech Republic;Spain;Austria;Netherlands | ||
| 7 | EUCTR2015-003679-31-AT (EUCTR) | 06/04/2016 | 11/01/2016 | New therapeutic strategy in Parkinson’s disease | Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II | De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE | Centre Hospitalier Régional et Universitaire de Lille | NULL | Not Recruiting | Female: yes Male: yes | 372 | Phase 2 | Portugal;France;Czech Republic;Spain;Austria;Netherlands;Germany;United Kingdom | ||
| 8 | EUCTR2015-004344-19-GB (EUCTR) | 31/03/2016 | 16/02/2016 | An international trial of deferiprone in patients with Parkinson’s disease | A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215 | Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone 600 mg delayed release tablet INN or Proposed INN: DEFERIPRONE | ApoPharma | NULL | Not Recruiting | Female: yes Male: yes | 140 | Phase 2 | France;Canada;Germany;United Kingdom | ||
| 9 | EUCTR2015-003679-31-ES (EUCTR) | 21/03/2016 | 13/01/2016 | New therapeutic strategy in Parkinson?s disease | Conservative iron chelation as a disease-modifying strategy in Parkinson?s disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone - FAIRPARK II | De Novo Parkinson?s disease MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Ferriprox 500 mg Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE | Centre Hospitalier Régional et Universitaire de Lille | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 338 | Phase 3 | Spain | ||
| 10 | NCT02655315 (ClinicalTrials.gov) | February 9, 2016 | 7/1/2016 | Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease | Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone | Parkinson Disease | Drug: Deferiprone;Drug: Placebo | University Hospital, Lille | European Commission;ApoPharma | Completed | N/A | 80 Years | All | 372 | Phase 2 | Austria;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;Czech Republic |
| 11 | EUCTR2015-003679-31-FR (EUCTR) | 25/01/2016 | 25/02/2016 | New therapeutic strategy in Parkinson’s disease | Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II | De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE | Centre Hospitalier Régional et Universitaire de Lille | NULL | Not Recruiting | Female: yes Male: yes | 338 | Phase 2 | Portugal;France;Czech Republic;Spain;Austria;Netherlands | ||
| 12 | NCT01539837 (ClinicalTrials.gov) | February 2012 | 22/2/2012 | A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease | A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease | Parkinson's Disease | Drug: Deferiprone 20mg;Drug: Placebo;Drug: Deferiprone 30mg | Imperial College London | NULL | Completed | 50 Years | 75 Years | All | 22 | Phase 2 | United Kingdom |
| 13 | EUCTR2011-001148-31-GB (EUCTR) | 13/09/2011 | 17/08/2011 | A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1 | A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1 | Parkinson's disease | Trade Name: Ferrprox (Deferiprone) Product Name: Deferiprone (Ferriprox) INN or Proposed INN: Deferiprone | Imperial College London | NULL | Not Recruiting | Female: yes Male: yes | 48 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom | ||
| 14 | NCT02880033 (ClinicalTrials.gov) | February 2011 | 3/8/2016 | Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes | Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis | Parkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron Overload | Drug: deferiprone;Drug: placebo | University Hospital, Lille | NULL | Completed | 18 Years | 80 Years | All | 90 | N/A | France |
| 15 | NCT00943748 (ClinicalTrials.gov) | October 2009 | 20/7/2009 | Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease | Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease | Parkinson's Disease | Drug: deferiprone;Drug: placebo | University Hospital, Lille | NULL | Completed | 30 Years | 80 Years | Both | 40 | Phase 2/Phase 3 | France |
18. Spinocerebellar degeneration
Clinical trials : 76 / Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-010865-22-IT (EUCTR) | 06/05/2009 | 16/04/2009 | An open-label, single treatment, safety and efficacy, long-term study of deferiprone in subjects with Friedreich?s ataxia - ND | An open-label, single treatment, safety and efficacy, long-term study of deferiprone in subjects with Friedreich?s ataxia - ND | patients affected by Friedreich Ataxia | INN or Proposed INN: Deferiprone | APOPHARMA INC., TORONTO, ONTARIO | NULL | Not Recruiting | Female: yes Male: yes | 74 | Belgium;France;Spain;Italy | |||
| 2 | EUCTR2007-003331-23-IT (EUCTR) | 16/07/2008 | 10/07/2008 | A study investigating the safety and tolerability of deferiprone in patients with Friedreich's Ataxia - ND | A study investigating the safety and tolerability of deferiprone in patients with Friedreich's Ataxia - ND | patients affected by Friedreich Ataxia MedDRA version: 9.1;Level: LLT;Classification code 10017374;Term: Friedreich's ataxia | Product Name: Deferiprone INN or Proposed INN: Deferiprone | APOPHARMA INC., TORONTO, ONTARIO | NULL | Not Recruiting | Female: yes Male: yes | 80 | United Kingdom;Belgium;France;Spain;Italy |
120. Hereditary dystonia
Clinical trials : 26 / Drugs : 19 - (DrugBank : 3) / Drug target genes : 2 - Drug target pathways : 2
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04184453 (ClinicalTrials.gov) | December 23, 2019 | 29/11/2019 | Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients | Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients | Aceruloplasminemia | Drug: Deferiprone treated | First Affiliated Hospital of Fujian Medical University | NULL | Recruiting | 18 Years | 80 Years | All | 5 | Early Phase 1 | China |
| 2 | NCT02635841 (ClinicalTrials.gov) | June 16, 2016 | 17/12/2015 | Compassionate Use of Deferiprone in Patients With PKAN | The Compassionate Use of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration | Pantothenate Kinase-Associated Neurodegeneration | Drug: Deferiprone | Chiesi Canada Corp | NULL | No longer available | 7 Years | N/A | All | NULL | ||
| 3 | EUCTR2014-001427-79-GB (EUCTR) | 30/12/2015 | 05/11/2015 | An international open label trial of deferiprone in patients with iron storage brain disorders - an extension to TIRCON2012V1 (a randomised controlled trial of deferiprone in patients with iron storage brain disorders). | Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN) - TIRCON2012V1-EXT | Pantothenate Kinase-Associated Neurodegeneration (PKAN) MedDRA version: 18.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Ferriprox Product Name: Deferiprone 80 mg/mL oral solution INN or Proposed INN: Deferiprone Other descriptive name: Deferiprone | ApoPharma Inc | NULL | Not Recruiting | Female: yes Male: yes | 89 | Phase 3 | United States;Germany;Italy;United Kingdom | ||
| 4 | EUCTR2014-001427-79-DE (EUCTR) | 27/03/2015 | 27/03/2015 | An 18-month extension of an international trial of deferiprone in patients with iron storage brain disorders | Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN) - TIRCON | Pantothenate kinase-associated neurodegeneration (PKAN);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: deferiprone 80 mg/mL oral solution INN or Proposed INN: DEFERIPRONE | ApoPharma Inc. | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 3 | United States;Germany;Italy;United Kingdom | ||
| 5 | NCT02174848 (ClinicalTrials.gov) | June 2014 | 5/6/2014 | Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration | Long-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN) | Pantothenate Kinase-Associated Neurodegeneration | Drug: Deferiprone oral solution | ApoPharma | NULL | Completed | 5 Years | N/A | All | 68 | Phase 3 | United States;Germany;Italy;United Kingdom |
| 6 | EUCTR2012-000845-11-GB (EUCTR) | 24/10/2013 | 19/09/2013 | An international trial of deferiprone in patients with iron storage brain disorders | A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN) - TIRCON | Pantothenate Kinase-Associated Neurodegeneration (PKAN) MedDRA version: 16.0;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Ferriprox Product Name: Deferiprone 80 mg/mL oral solution (Ferriprox) INN or Proposed INN: Deferiprone Other descriptive name: Deferiprone | ApoPharma Inc | NULL | Not Recruiting | Female: yes Male: yes | 90 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United States;Poland;Germany;Italy;United Kingdom | ||
| 7 | EUCTR2012-000845-11-IT (EUCTR) | 24/10/2013 | 31/07/2013 | An international trial of deferiprone in patients with iron storage brain disorders | A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN) - TIRCON | Pantothenate kinase-associated neurodegeneration (PKAN);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone 80 mg/mL oral solution INN or Proposed INN: Deferiprone Other descriptive name: Deferiprone | ApoPharma Inc. | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 3 | United States;Poland;Germany;United Kingdom;Italy | ||
| 8 | NCT01741532 (ClinicalTrials.gov) | December 13, 2012 | 3/12/2012 | Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) | A Randomized, Double-blind, Placebo-controlled Trial of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) | Pantothenate Kinase-Associated Neurodegeneration | Drug: Deferiprone oral solution;Drug: Placebo | ApoPharma | Food and Drug Administration (FDA) | Completed | 4 Years | N/A | All | 89 | Phase 3 | United States;Germany;Italy;United Kingdom;Poland |
| 9 | EUCTR2012-000845-11-DE (EUCTR) | 16/07/2012 | 30/03/2012 | An international trial of deferiprone in patients with iron storage brain disorders | A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN) - TIRCON | Pantothenate kinase-associated neurodegeneration (PKAN);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Deferiprone 80 mg/mL oral solution INN or Proposed INN: Deferiprone Other descriptive name: Deferiprone | ApoPharma Inc. | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 3 | United States;Poland;Germany;United Kingdom;Italy | ||
| 10 | EUCTR2008-003059-56-IT (EUCTR) | 29/07/2008 | 18/07/2008 | Phase II trial to assess safety and efficacy of Iron chelating agent Deferiprone in patients with Pantothenate Kinase-Associated Neurodegeneration ? ICAND ? Trial - ND | Phase II trial to assess safety and efficacy of Iron chelating agent Deferiprone in patients with Pantothenate Kinase-Associated Neurodegeneration ? ICAND ? Trial - ND | PKAN MedDRA version: 9.1;Level: HLT;Classification code 10042259;Term: Structural brain disorders NEC | Trade Name: FERRIPROX*100CPR RIV 500MG INN or Proposed INN: Deferiprone | ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | Italy | |||
| 11 | EUCTR2014-001427-79-IT (EUCTR) | 04/06/2021 | An 18-month extension of an international trial of deferiprone in patients with iron storage brain disorders | Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN) - Long-term safety and efficacy study of deferiprone in patients with pantothenate kinase-associated n | Pantothenate Kinase-Associated Neurodegeneration (PKAN) MedDRA version: 21.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: deferiprone 80 mg/mL oral solution INN or Proposed INN: DEFERIPRONE Other descriptive name: DEFERIPRONE | APOTEX EUROPE B.V. | NULL | Not Recruiting | Female: yes Male: yes | 89 | Phase 3 | United States;Germany;United Kingdom;Italy |
122. Superficial siderosis
Clinical trials : 3 / Drugs : 3 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000021218 | 2024/09/30 | 26/02/2016 | Evaluation of iron chelator administration, and cochlear implantation for superficial siderosis (ECHACISS) | Evaluation of iron chelator administration, and cochlear implantation for superficial siderosis (ECHACISS) - ECHACISS | superficial siderosis of CNS | deferiprone administration cochlear implantation | Department of Neurology, Tokyo Medical and Dental University | Department of Neurology, Kouchi University Hospital | Recruiting | 20years-old | Not applicable | Male and Female | 5 | Not applicable | Japan |
| 2 | JPRN-jRCTs031180438 | 01/04/2019 | 27/03/2019 | Evaluation of iron chelator administration, and cochlear implantation for superficial siderosis | Evaluation of iron chelator administration, and cochlear implantation for superficial siderosis - ECHACISS | Superficial siderosis siderosis, cerebellar ataxia, hearing loss, superficial siderosis | 1. Administration of Deferiprone orally 30mg/kg after every meal for 36 months. 2. Artificial cochlear implantation for severe hearing disturbance | Sanjo Nobuo | NULL | Recruiting | >= 20age old | Not applicable | Both | 50 | N/A | Japan |
233. Wolfram syndrome
Clinical trials : 11 / Drugs : 17 - (DrugBank : 8) / Drug target genes : 12 - Drug target pathways : 41
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02882477 (ClinicalTrials.gov) | December 2016 | 17/7/2016 | Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy | Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy | Diabetes Mellitus;Iron Metabolism Disorders;Gastroduodenal Ulcer;Optic Atrophy;Sensorineural Hearing Loss;Platelet Dysfunction | Drug: Deferiprone;Drug: Acetylcysteine;Drug: Sitagliptin and Metformin | Hadassah Medical Organization | NULL | Not yet recruiting | 3 Years | N/A | Both | 20 | Phase 2/Phase 3 | Israel |